AAV1.NT-3 Gene Therapy for Charcot–Marie–Tooth Neuropathy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Charcot-Marie-Tooth (CMT) neuropathies represent a heterogeneous group of peripheral nerve disorders affecting 1 in 2,500 persons. One variant, CMT1A, is a primary Schwann cell (SC) disorder, and represents the single most common variant. In previous studies, we showed that neurotrophin-3 (NT-3) improved the trembler(J) (Tr(J)) mouse and also showed efficacy in CMT1A patients. Long-term treatment with NT-3 was not possible related to its short half-life and lack of availability. This led to considerations of NT-3 gene therapy via adenoassociated virus (AAV) delivery to muscle, acting as secretory organ for widespread distribution of this neurotrophic agent. In the Tr(J) model of demyelinating CMT, rAAV1.NT-3 therapy resulted in measurable NT-3 secretion levels in blood sufficient to provide improvement in motor function, histopathology, and electrophysiology of peripheral nerves. Furthermore, we showed that the compound muscle action potential amplitude can be used as surrogate for functional improvement and established the therapeutic dose and a preferential muscle-specific promoter to achieve sustained NT-3 levels. These studies of intramuscular (i.m.) delivery of rAAV1.NT-3 serve as a template for future CMT1A clinical trials with a potential to extend treatment to other nerve diseases with impaired nerve regeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potentiation of developing neuromuscular synapses by the neurotrophins NT-3 and BDNF
Lohof, A. M., Ip, N. Y., & Poo, M.-M. (1993) · Nature · doi:10.1038/363350a0 · Cited by 755
Poduslo, J. F., & Curran, G. L. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00250-v · Cited by 614
Self-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515
Cited by
Keefe, K., Sheikh, I., & Smith, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030548 · Cited by 322
Modern Trends for Peripheral Nerve Repair and Regeneration: Beyond the Hollow Nerve Guidance Conduit
Carvalho, C. R., Oliveira, J. M., & Reis, R. L. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00337 · Cited by 297
AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models
Sondergaard, P. C., Griffin, D. A., Pozsgai, E. R., Johnson, R. W., Grose, W. E., Heller, K. N., Shontz, K. M., Montgomery, C. L., Liu, J., Clark, K. R., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.172 · Cited by 99
Self-citationPositive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease
Forsell, P., Parrado Fernández, C., Nilsson, B., Sandin, J., Nordvall, G., & Segerdahl, M. (2024) · Pharmaceuticals · doi:10.3390/ph17080997 · Cited by 14
Tong, L., Ozes, B., Moss, K., Myers, M., Attia, Z., Vetter, T. A., Trapp, B. D., & Sahenk, Z. (2025) · Gene Therapy · doi:10.1038/s41434-025-00518-9 · Cited by 8
Self-citation
Metadata
- Authors
- Sahenk, Z., Galloway, G., Clark, K. R., Malik, V., Rodino-Klapac, L. R., Kaspar, B. K., Chen, L., Braganza, C., Montgomery, C., & Mendell, J. R.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 22
- Issue
- 3
- Pages
- 511-521
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2062060047
- Cited by
- 103
- References
- 3
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.